Paris - Delayed Quote EUR
ABIVAX Société Anonyme (ABVX.PA)
5.30
+0.04
+(0.76%)
At close: May 21 at 5:35:33 PM GMT+2
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Marc M. P. de Garidel M.B.A. | CEO & Director | 630.94k | -- | 1958 |
| Mr. Didier Blondel | EVP, CFO & Board Secretary | -- | -- | 1964 |
| Mr. Didier Scherrer Ph.D. | Chief Scientific Officer | -- | -- | 1970 |
| Mr. Patrick Malloy | Senior Vice President of Investor Relations | -- | -- | -- |
| Ms. Ida Hatoum | Chief People & Compliance Officer | -- | -- | 1975 |
| Mr. Pierre Courteille M.B.A. | Chief Business Officer | -- | -- | 1969 |
| Mr. Jerome Denis Ph.D. | Executive Vice President of Process Development & Manufacturing | -- | -- | -- |
| Hema Keshava | Senior Vice President of Finance | -- | -- | -- |
| Chris Rabbat Ph.D. | VP & Global Head of Medical Affairs | -- | -- | -- |
| Kevin Shan Ph.D. | VP & Global Head of Biometrics | -- | -- | -- |
ABIVAX Société Anonyme
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 69
Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Corporate Governance
ABIVAX Société Anonyme’s ISS Governance QualityScore as of May 1, 2025 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 7; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
June 2, 2025 at 2:00 PM UTC
ABIVAX Société Anonyme Earnings Date
Recent Events
Recent Events Information Not Available
Related Tickers
AYJ.F Valneva SE
2.8040
-2.30%
HPHA.DE Heidelberg Pharma AG
3.2700
0.00%
VVY.AS Vivoryon Therapeutics N.V.
1.7980
+0.11%
SIGHT.PA GenSight Biologics S.A.
0.1998
-0.60%
ALCLS.PA Cellectis S.A.
1.3420
+0.30%
ALSEN.PA Sensorion SA
0.2920
-5.81%
PRTCl.XC
9LB.MU Legend Biotech Corp
25.60
-2.29%
1GDA.F Zevra Therapeutics, Inc.
7.55
+0.67%
048410.KQ Hyundai Bioscience Co., Ltd.
11,300.00
+7.52%